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Abstract
Evidence indicates that disruption of normal prenatal development influences an individual’s risk of developing obesity and
cardiovascular disease as an adult. Thus, understanding how in utero exposure to chemical agents leads to increased
susceptibility to adult diseases is a critical health related issue. Our aim was to determine whether adenosine A1 receptors
(A1ARs) mediate the long-term effects of in utero caffeine exposure on cardiac function and whether these long-term effects
are the result of changes in DNA methylation patterns in adult hearts. Pregnant A1AR knockout mice were treated with
caffeine (20 mg/kg) or vehicle (0.09% NaCl) i.p. at embryonic day 8.5. This caffeine treatment results in serum levels
equivalent to the consumption of 2–4 cups of coffee in humans. After dams gave birth, offspring were examined at 8–10
weeks of age. A1AR+/+ offspring treated in utero with caffeine were 10% heavier than vehicle controls. Using
echocardiography, we observed altered cardiac function and morphology in adult mice exposed to caffeine in utero.
Caffeine treatment decreased cardiac output by 11% and increased left ventricular wall thickness by 29% during diastole.
Using DNA methylation arrays, we identified altered DNA methylation patterns in A1AR+/+ caffeine treated hearts, including
7719 differentially methylated regions (DMRs) within the genome and an overall decrease in DNA methylation of 26%.
Analysis of genes associated with DMRs revealed that many are associated with cardiac hypertrophy. These data
demonstrate that A1ARs mediate in utero caffeine effects on cardiac function and growth and that caffeine exposure leads
to changes in DNA methylation.
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Introduction
Increasing evidence indicates that alteration of normal prenatal
development influences an individual’s lifetime risk of developing
obesity and cardiovascular disease [1–6]. Thus, understanding
how in utero exposure to chemical agents leads to increased
susceptibility to adult diseases is an important issue.
One substance that fetuses are frequently exposed to is caffeine,
a non-selective adenosine receptor antagonist. Caffeine consump-
tion during the first month of pregnancy is reported by 60% of
women, and 16% of pregnant mothers report consuming 150 mg
or more per day [7]. Caffeine exerts many cellular effects,
including influences on intracellular calcium levels and inhibition
of phosphodiesterase; however, at serum concentrations observed
with typical human consumption, the major effects of caffeine are
due to a blockade of adenosine action at the level of adenosine
receptors through competitive inhibition [8].
Adenosine levels increase dramatically under physiologically
stressful conditions that include hypoxia, tissue ischemia, and
inflammation [9–11]. Adenosine acts via cell surface G-protein
coupled receptors, including A1, A2a, A2b, and A3 adenosine
receptors [12]. Of these adenosine receptors, A1 adenosine
receptors (A1ARs) have the highest affinity for adenosine and
are the earliest expressed adenosine receptor subtype in the
developing embryo [12,13]. Showing how adenosine plays an
important role in development, recent data indicate that a single
dose of caffeine given to pregnant mice leads to reduced
embryonic heart size and impaired cardiac function in adulthood
[14]; however, the mechanisms by which these effects occur are
not known.
At present, our understanding of the long-term effects of in utero
caffeine exposure remains modest. In animal models, embryonic
caffeine exposure leads to teratogenic effects, including ventricular
septal defects and intrauterine growth retardation (IUGR) [14–
19]. Other studies show that caffeine exposure as early as
embryonic day 10.5 (E10.5) in mice can cause reduced embryonic
cardiac tissue [14]. In addition, caffeine can induce defects in
angiogenesis in zebrafish (Danio rerio) embryos [14,20]. In mice and
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zebrafish, caffeine affects embryonic cardiac function by increasing
heart rates [21,22]. Caffeine exposure increases expression of the
cardiac structural gene myosin heavy chain alpha (Myh6) in fetal
rat hearts [23]. In humans, there is little evidence that fetal caffeine
exposure leads to morphological defects, but prenatal caffeine
exposure is associated with an increased risk of spontaneous
abortions and reduced birth weight [24–31]. Studies examining
the long-term consequences of in utero caffeine exposure in humans
have not been performed.
One recognized mechanism for transmitting in utero stress into
an increased risk of adult disease involves epigenetic changes that
include altered DNA methylation, post-translational modifications
of histone tails, and miRNA regulation [32,33]. Changes in DNA
methylation patterns occurring normally during early embryogen-
esis can be influenced by nutritional and environmental factors
resulting in long lasting effects in adulthood [34–36].
To provide further insights into adenosine and caffeine action in
the embryo, we assessed the role of A1ARs in transducing the
embryonic effects of caffeine in the mouse model. We also assessed
the effects of caffeine on epigenetic modifications specifically DNA
methylation patterns, and finally we examined caffeine’s long-term
effects on the heart.
Methods
Ethics Statement
All animal experiments were approved by the Institutional
Animal Care and Use Committee (IACUC) at Yale University. All
animal research was conducted at Yale University and concluded
before corresponding author moved to the University of Florida
College of Medicine.
Animals
Adenosine A1 receptor (A1AR) deficient mice were provided by
Dr. Bertil Fredholm at the Karolinska Institutet in Stockholm,
Sweden and were characterized [37]. These mice are on a mixed
background (129/OlaHsd/C57BL) and breed normally with
expected Mendelian frequency.
Timed matings were performed with A1AR+/2 males and
A1AR+/2 females, and the day a vaginal plug was observed was
designated as embryonic day 0.5 (E0.5). Pregnant dams were
randomized into two groups and injected intraperitoneally (i.p.) at
E8.5. This stage is a critical time during cardiac development
when the heart has begun to function, the heart valves are
forming, and the heart is beginning to loop in order to bring the
different chambers of the heart into proper alignment [38,39]. In
addition, treatment of pregnant dams at E8.5 was chosen because
it is during the embryonic development window (E6.5–10.5) when
genomic DNA is being re-methylated [40], thus E8.5 is a stage
sensitive to DNA methylation disruption. Group 1 was injected
with vehicle 0.9% NaCl, and group 2 was injected with 20 mg/kg
of caffeine (Sigma-Aldrich, St. Louis, MO, USA) dissolved in
vehicle. This caffeine treatment results in circulating blood levels
equivalent to the consumption of 2–4 cups of coffee in humans and
65% A1AR occupancy [8,14]. Analysis was performed on male
offspring divided into six groups based on treatment and genotype;
including 1) vehicle/A1AR+/+ (veh+/+), 2) vehicle/A1AR+/2
(veh+/2), 3) vehicle/A1AR2/2 (veh2/2), 4) caffeine/
A1AR+/+ (caff+/+), 5) caffeine/A1AR+/2 (caff+/2), and 6)
caffeine/A1AR2/2 (caff2/2). Adult offspring for each group
were obtained from at least 4 different dams. Adult offspring were
used for nuclear magnetic resonance (NMR), weights, and
echocardiography. The number of male offspring produced for
these experiments came from 11 dams treated with vehicle
including 8 A1AR+/+, 24 A1AR+/2, and 8 A1AR 2/2, and 9
dams treated with caffeine including 8 A1AR+/+, 17 A1AR+/2,
and 11 A1AR2/2. Of these mice some died before NMR and
echocardiography, the Ns for each experiment are provided in the
figure legends. In addition, 3–4 hearts from each group were used
for histology and 3–4 hearts per group were used for RNA and
DNA isolation. After birth, mice were weighed weekly from 2–8
weeks of age. Mice were euthanized by CO2 inhalation followed
by cervical dislocation.
Nuclear magnetic resonance
Between 8–10 weeks of age, the vehicle- and caffeine-treated
male mice were evaluated by NMR at the Yale Metabolic
Phenotyping Center, as described [14,41]. Animals were placed in
a restraint cylinder for body composition analysis using the
Minispec Benchtop NMR (Bruker Optics, Billerica, MA, USA).
NMR analysis was used to assess absolute fat, lean mass, and free
body fluid content, based on total body weight. Data were used to
determine percent body fat (fat mass/total body mass6100).
Echocardiography
Cardiac function of male offspring was assessed using echocar-
diography between 8–10 weeks of life, as described [14,42].
Offspring were anesthetized with a continuous flow of isoflurane
administered via nosecone and anesthesia levels were regulated to
maintain heart rates between 400 and 500 beats per minute.
Transthoracic 2D M-mode echocardiography was performed
using a 30-MHz probe (Vevo 770; Visualsonics, Toronto, ON,
Canada) [14]. Echocardiography and analysis of results were
performed blinded.
The hemodynamic effects of caffeine treatment were assessed in
dams as described [43]. Briefly, baseline data on heart rate and
cardiac function were obtained as described above. Animals were
allowed to recover for 30 minutes followed by treatment with
either 0.9% NaCl (vehicle) or 20 mg/kg of caffeine. Echocardi-
ography was then performed 30 minutes after treatment.
Adult cardiac histology
Adult hearts of male offspring were fixed by perfusion of hearts
with 4% paraformaldehyde solution (PFA; Electron Microscopy
Figure 1. Embryonic caffeine exposure leads to increased
weight in adulthood. Male mice treated in utero with caffeine were
weighed every week starting 2 weeks after birth. Between 3–8 weeks of
age, caffeine/A1AR+/+ mice were significantly heavier than vehicle/
A1AR+/+ mice. Two-way ANOVA with Bonferroni post-test comparison
was performed. *P#0.05, **P#0.01, ***P#0.001. N = 8.
doi:10.1371/journal.pone.0087547.g001
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Sciences, Hatfield, PA, USA) containing 150 mM KCl and 5 mM
EDTA. Hearts were embedded in paraffin, sectioned, mounted on
slides, and analyzed as described [14].
DNA methylation array analysis
Methylated DNA immunoprecipitation (MeDIP) and Nimble-
Gen DNA methylation microarrays were used to assess changes in
DNA methylation patterns between caffeine- and vehicle-treated
adult male mice. The groups studied included: caff+/+, caff2/2,
veh+/+, and veh2/2 mice. Two samples from each treatment
group were used to generate the DNA methylation array data,
which was then used for all subsequent pathway analyses. The use
of 1 to 2 samples per group is common for this type of analysis, so
our use of two samples is consistent with previously published
reports [44,45]. Genomic DNA from left ventricles was isolated
using the DNeasy Blood & Tissue Kit (Qiagen, Valencia, CA,
USA). MeDIP was performed by following the NimbleGen DNA
Methylation Microarrays Sample Preparation Instructions. Both
MeDIP-enriched and non-enriched DNA were amplified using the
GenomePlex Complete Whole Genome Amplification Kit (Sigma-
Aldrich). Amplified DNA was hybridized to the Mouse DNA
Methylation 2.1 M Deluxe Promoter Arrays (Roche NimbleGen,
Madison, WI, USA) according to manufacturer’s protocol.
DNA methylation array data were analyzed using methods
developed by Palmke et al. 2011 [44] and by Tobias Straub
(http://www.protocol-online.org/cgi-bin/prot/view_cache.cgi?ID=3
973). Data were normalized within (Lowess-based) and between
(quantile-based) arrays and probe level log2 ratio of Cy5/Cy3
(M-value) was used as a measure of MeDIP enrichment [46].
All DNA methylation array data were uploaded to the Gene
Figure 2. Embryonic caffeine exposure leads to thickening of left ventricular walls. Cardiac morphology was analyzed in adult mice by
echocardiography at 8–10 weeks of age. (A) Caffeine-treated A1AR+/+ left ventricles were heavier than vehicle treated controls. Caffeine treatment of
A1AR+/+mice also caused increased thickness of the left ventricular posterior wall (LVPW) in both diastole (B) and systole (C), and increased thickness
of the interventricular septum (IVS) in both diastole (D) and systole (E) when compared to vehicle controls. Vehicle/A1AR+/+, N = 6; Vehicle/A1AR +/2,
N = 23; Vehicle/A1AR 2/2, N = 8; caffeine/A1AR+/+, N = 6, caffeine/A1AR+/2, N = 15; caffeine/A1AR2/2, N = 10. Two-way ANOVA with Bonferroni
post-test comparison was performed. *P#0.05.
doi:10.1371/journal.pone.0087547.g002
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Expression Omnibus (GEO) and can be accessed via http://
www.ncbi.nlm.nih.gov/geo/; accession number GSE43030.
Chromosomal distribution of DMR regions were analyzed by
using Enrichment on Chromosome and Annotation (CEAS) in
Galaxy/Cistrome [47]. Venn diagrams were constructed with
Galaxy/Cistrome [47].
Pathway analysis of the genes associated with the DMRs was
conducted using MetaCore Enrichment Analysis (Version 6.11,
build 41105; GeneGo, Carlsbad, CA, USA) and Ingenuity
Pathway Analysis (Ingenuity Systems, Redwood City, CA, USA).
The lists of differentially methylated genes and miRNAs were
uploaded separately into the applications. MetaCore enrichment
ontologies used included Pathway Maps, Map Folders, Process
Networks, Diseases (by Biomarkers), and Disease Biomarker
Networks. Ingenuity ontologies analyzed included IPA Core
Analysis and IPA-Tox.
Bisulfite sequencing (BS-seq) was used to analyze the DMRs
within the gene promoters and performed as described [48].
Bisulfite specific primers were designed with Methyl Primer
Express v1.0 (Applied Biosystems, Carlsbad, CA, USA). Sequence
data were analyzed with DNAstar (SeqMan, Madison, WI, USA).
The CpG methylation percentage was calculated as (total number
of methylated CpG)/(number of CpG sites in each gene6number
of colonies sequenced).
Global DNA methylation and hydroxymethylation
Global DNA methylation and hydroxymethylation of the left
ventricular genomic DNA were measured with the MethylFlash
Figure 3. Embryonic caffeine exposure leads to altered cardiac function. Cardiac function of mice exposed to in utero caffeine was analyzed
by echocardiography between 8–10 weeks of age. Analysis revealed that A1AR+/+ caffeine-treated mice had reduced stroke volume (A), increased %
fractional shortening (B), reduced left ventricular internal diameter (LVID) in both diastole (C) and systole (D), and reduced left ventricle volume at
both diastole (E) and systole (F). Vehicle/A1AR+/+, N = 6; Vehicle/A1AR+/2, N = 23; Vehicle/A1AR2/2, N = 8; caffeine/A1AR+/+, N = 6, caffeine/
A1AR+/2, N = 15; caffeine/A1AR2/2, N = 10. Two-way ANOVA with Bonferroni post-test comparison was performed. *P#0.05.
doi:10.1371/journal.pone.0087547.g003
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Methylated DNA Quantification Kit and MethylFlash Hydro-
xymethylated DNA Quantification Kit (Colorimetric; Epigentek
Group, Farmingdale, NY, USA) according to the manufacturer’s
protocols. The OD450 nm intensity of the colorimetric reaction
was measured with Synergy HT Multi-Mode Microplate Reader
(BioTek, Winooski, VT, USA). Each sample was measured in
triplicate, and assays were repeated twice.
Real-time PCR analysis
Total RNA from left ventricles of adult male offspring was
extracted with RNeasy Plus Mini Kit (Qiagen), according to the
manufacturer’s protocol. cDNA was synthesized using iScript
cDNA Synthesis Kit (Bio-Rad, Hercules, CA, USA). Primers were
as follows: Mef2c forward: GATGCCATCAGTGAATCAAAGG;
Mef2c reverse: GTTGAAATGGCTGATGGATATCC; Tnnt2
forward: CTGAGACAGAGGAGGCCAAC; Tnnt2 reverse:
TTCTCGAAGTGAGCCTCCAT. For Myh6 and Myh7, primers
were designed and synthesized by SABiosciences (Qiagen). For b-
actin, primers were designed and synthesized by RealTimePri-
mers.com (Elkins Park, PA, USA), b-actin forward: AAGAGC-
TATGAGCTGCCTGA, b-actin reverse: TACGGATGT-
CAACGTCACAC. Relative abundance of target genes to b-
actin transcripts in the cDNA libraries was determined with
SYBRHGreen (Applied Biosystems) in a GeneAmp 7300 Real
Time PCR System (Applied Biosystems). Each sample was
measured in three separate reactions on the same plate. This
assay was repeated three times. Amplification efficiencies of the
target genes and b-actin primer pairs were tested to ensure that
they were not statistically different. Differences in expression
between the treatment groups were calculated with the 22DDCT
method. Statistical differences between treatments were deter-
mined on the linearized 22DCT values.
Caffeine assay
Caffeine levels were measured in the serum of dams by ELISA
assay (Neogen, Lexington, KY, USA), as described [14]. A1AR
KO female mice were treated i.p. with 20 mg/kg of caffeine and
blood serum was collected 2 hours later.
Statistical Analysis
Data are presented as means 6 the standard error of the mean
(SEM). Analysis was performed with the statistics software package
included with Microsoft Excel (Microsoft, Redmond, WA, USA)
and GraphPad Prism 6.0 (GraphPad Software Inc., La Jolla, CA,
USA). Statistical comparisons between groups were performed
with student’s t-test assuming equal variance or with one-way or
two-way ANOVA with Bonferroni’s post-test comparison. P#0.05
was considered to be statistically significant.
Results
Caffeine treatment has no effect on maternal cardiac
function
Female A1AR+/+ mice treated with a caffeine dose of 20 mg/
kg were analyzed for serum caffeine levels and cardiac function.
This dose of caffeine results in a circulating serum caffeine level of
37.561.5 mM (N=3), similar to that observed in C57Bl/6 mice
[14]. To test if caffeine treatment alters the hemodynamics of
treated dams, we measured the heart rates as beats per minute
(bpm) and cardiac outputs as milliliters per minute (ml/min) of
adult mice before and 30 minutes after treatment with either
vehicle or 20 mg/kg of caffeine. There was no significant
difference with caffeine treatment in heart rate from baseline
(44766 bpm) to 30 min after caffeine treatment (462612.5 bpm,
N=4), or in cardiac output from baseline (14.861.6 ml/min) to
30 min after caffeine treatment (15.060.6 ml/min, N= 4). As a
control dams were treated with vehicle (0.9% NaCl), and no
significant differences were observed in heart rate between
baseline (442618 bpm) and 30 min after vehicle (47868 bpm,
N=4)) or in cardiac output from baseline (14.760.6 ml/min) to
30 min after vehicle (15.761.7 ml/min, N=4). In addition, no
significant differences were observed between either baseline or
peak heart rate or cardiac output when comparing vehicle to
caffeine treated mice.
In utero caffeine treatment leads to higher body weight
in adult male mice
Pregnant dams were treated with one 20 mg/kg dose of caffeine
or vehicle (0.9%NaCl) at E8.5. Male offspring were weighed weekly
until 8 weeks of age. Beginning at 3 weeks of age, the caff+/+ mice
were heavier than the veh+/+ controls (Fig. 1). The increase in body
weight persisted throughout the study, caff+/+ mice weighed on
average 2.47 grams more than veh+/+ controls. Because the
absolute difference in body weight between the two groups was
constant throughout the study, the percent increase in body weight
peaked at 3 weeks with caff+/+ mice weighing 23.9% more than
veh+/+ controls, and by 8 weeks of age the caff+/+mice were 10%
heavier than veh+/+ mice (Fig.1). Only A1AR+/+ mice treated
with caffeine were significantly heavier in adulthood compared to
A1AR+/+ controls. Comparisons of body weights between veh+/2
(N= 20) and caff+/2 (N=15) or between veh2/2 (N= 6) and
caff2/2 (N= 10) were not significantly different.
In addition to assessing body weight, we analyzed body fat in
adult offspring by NMR. Even though there was a significant
difference in body weight between the caffeine-treated group and
the vehicle-treated group at the time NMRs were performed (two-
way ANOVA, P#0.04), no differences in the body fat content
were detected among the different groups. The average percent
body fat for the different treatment groups were veh+/+
6.8161.1% (N=8), veh+/2 6.3160.5% (N=20), veh2/2
6.760.9% (N=6), caff+/+ 6.9660.8% (N=8), caff+/2
6.2260.8% (N=15), and caff2/2 7.2560.8% (N=10). There
was no difference in the percent muscle weight among the
caffeine- and vehicle-treated groups (data not shown).
Figure 4. No effect on connective tissue deposition in adult
hearts was observed with caffeine treatment. Adult hearts from
mice exposed to in utero caffeine examined with trichrome stain to
reveal heart muscle structure and connective tissue deposition. No
differences in the amount of connective tissue deposition were
observed between (A) veh+/+ and (B) caff+/+ adult left ventricles.
However, caff+/+ left ventricles were thicker than veh+/+. N = 3. Scale
bars = 100 mM.
doi:10.1371/journal.pone.0087547.g004
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In utero caffeine treatment causes a thickening of the left
ventricular walls and altered cardiac function in adult
hearts
Cardiac function, wall thickness, and chamber size were
measured by echocardiography in the adult male offspring of
pregnant dams treated with caffeine or vehicle at E8.5. The groups
examined included caffeine- or vehicle-treated and three geno-
types (A1AR+/+, A1AR+/2, and A1AR2/2). Of these groups,
only the caff+/+ vs. veh+/+ comparison revealed significant
differences in cardiac function and morphology. Caffeine treat-
ment lead to changes in adult cardiac morphology in the caff+/+
mice, including a 24% increase in left ventricle (LV) mass
Figure 5. Embryonic caffeine exposure caused a change in DNA methylation patterns. Vehicle and caffeine treated mice with the same
genotype were compared to identify differentially methylated regions (DMRs) in the genome (A). The veh+/+ vs. caff+/+ comparison identified the
most differentially methylated regions in the genome following in utero caffeine exposure. Both (B) hypermethylated and (C) hypomethylated DMRs
were detected throughout the genome with each comparison. Most DMRs were detected within the gene or promoter regions of the genome. The
number of DNA samples per treatment group analyzed was 2.
doi:10.1371/journal.pone.0087547.g005
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compared to veh+/+ (Fig. 2A). In addition, caffeine caused an
increase in the thickness of both the left ventricular posterior wall
(LVPW) and the interventricular septum (IVS; Fig. 2). The LVPW
thickness was increased by 28.6% during diastole and 23.3%
during systole, whereas the IVS thickness was increased by 24.5%
during diastole and 14.3% during systole (Fig. 2).
The increased left ventricular wall thickness was associated with
a decrease in the left ventricular internal diameter (LVID) by
13.2% at diastole and 28.9% at systole (Fig. 3). The reduced LVID
was associated with reduced left ventricle volume, which led to a
12.5% decrease in the LV stroke volume (Fig. 3). The percent
fractional shorting (%FS) was increased in caffeine treated hearts
(Fig. 3), and cardiac output (CO) was reduced by 11.4% in caff+/+
(N= 6) mice compared to veh+/+ (N= 6) treated mice (P#0.02
student t-test). Although we observed differences in the cardiac
output for the caff+/+ group, overt heart failure was not observed.
Histological examination did not reveal differences in heart
muscle structure among any of the groups but the caff+/+ group
displayed thicker left ventricular walls compared to veh+/+
controls (Fig. 4). Trichrome staining indicated that there were
no differences in connective tissue deposition or any evidence of
scarring in adult hearts from any of the treatment groups (Fig.4).
In utero caffeine exposure alters the DNA methylation
pattern in adult hearts
NimbleGen DNA methylation microarrays were used to
investigate DNA methylation patterns in adult left ventricles.
The Mouse DNA Methylation 2.1 M Deluxe Promoter Array was
chosen because it interrogates DNA methylation in 599 miRNA
promoters including 15 kb upstream of the transcriptional start
site (TSS), 15,969 gene promoters regions that range from
8,000 bp upstream to 3,000 bp downstream of the TSS, and
24,507 known CpG islands in the genomic DNA. For the DNA
methylation analysis, four groups were studied including veh+/+,
veh2/2, caff+/+, and caff2/2 groups. This analysis identified
changes in DNA methylation patterns that were caffeine- and
A1AR-dependent (veh+/+ vs. caff+/+), caffeine-dependent and
A1AR-independent (veh2/2 vs. caff2/2), and A1AR-depen-
dent and caffeine-independent (veh+/+ vs. veh2/2).
Analysis of the different groups revealed that the veh+/+ vs.
caff+/+ comparison had the greatest number of differentially
methylated regions (DMRs) within the genomic DNA including
both hypermethylated regions (4896) and hypomethylated regions
(2823; Fig. 5A). Caffeine altered the DNA methylation pattern in
the absence of A1AR expression (A1AR2/2 mice) to a lesser
degree than in A1AR+/+ mice. For example, the comparison of
Figure 6. Distribution of the differentially methylated regions. (A) A Venn diagram indicates the number of DMRs that are shared by different
comparison groups. The majority of DMRs within a comparison group are unique to that group with few regions detected in multiple comparison
groups, and only 69 DMRs present in all three comparisons. (B) This chart illustrates locations in the genome for the DMRs identified from the veh+/+
vs. caff+/+ comparison. Analysis demonstrates that promoter regions from21 to23000 and intron regions contain the greatest percentage of DMRs.
(C) In this chart, pink bars represent the percent of the genome that each chromosome contains and the blue bars are the percent of the total
number of DMRs that are located on each chromosome. This chart identifies chromosomes 2, 7, and 11 as having the highest percentage of DMRs.
N = 2.
doi:10.1371/journal.pone.0087547.g006
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veh2/2 vs. caff2/2 only had 1024 hypermethylated regions and
1757 hypomethylated regions (Fig. 5A). In addition, the loss of
A1AR expression alone altered DNA methylation patterns
(Fig. 5A). Analysis of the differentially methylated regions revealed
where in the genome the DMRs (either hypermethylated or
hypomethylated) were located, including promoter regions,
primary transcripts, known CpG islands or miRNA promoter
regions (Fig. 5B, C).
A Venn diagram demonstrating the number of over-lapping
DMRs from the different comparison groups indicated that the
majority of DMRs are specific to each of the comparison groups
(Fig. 6). The majority of DMRs in the veh+/+ vs. caff+/+ group
were located in promoter regions less than 3,000 bp from the
transcriptional start site (TSS) and in introns (Fig. 6). Further
analysis of veh+/+ vs. caff+/+ identified the percentage of the total
number of DMRs that were located on each chromosome (Fig. 6).
The highest percentages of DMRs were located on chromosomes
2, 7 and 11, while the lowest percentage of DMRs was found on
chromosome Y (Fig. 6).
Caffeine treatment alters DNA methylation of genes
associated with cardiac hypertrophy
Because the veh+/+ vs. caff+/+ comparison revealed pheno-
typic differences in cardiac function and the highest degree of
DNA methylation differences, all 7719 DMRs identified from this
comparison, both hyper- and hypomethylated regions, were used
for gene pathway analysis. Genes associated with these DMRs
were examined with the functional ontology enrichment tool from
MetaCore. MetaCore uses different manually created groupings of
Figure 7. Significantly enriched cardiovascular related pathways. Gene set enrichment analysis was done with the differentially methylated
genes between A1AR+/+mice treated with or without caffeine. The analysis was conducted with MetaCore Enrichment Analysis using the ontologies
of Diseases (by Biomarkers), Map Folders, Pathway Maps, and Process Networks. Bars represent the percentage of altered methylation genes (in black)
within a pathway. The numbers of altered genes and genes in a pathway are listed next to the bars, which represent the percentage of altered genes
within a pathway. Dots indicate the negative log 10 of the P-values. Larger –log(P-value) means that the pathway is more significant. The threshold
for significance is marked in the graph as a dotted-line at 1.3 (2log(0.05)). N = 2.
doi:10.1371/journal.pone.0087547.g007
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genes from different databases, including common cellular
processes, networks, biological function, and disease, which are
referred to as ontologies. These ontologies are used to identify
gene pathways that contain genes associated with differentially
methylated regions of the genome.
Table 1. Top 20 most significantly enriched pathways analyzed with MetaCoreTMontology (N= 2).
# Pathways p-value
# of changed
genes
# of genes in
pathway
Pathway
map folders
1 Cell differentiation 1.740e-23 264 928
2 Inflammatory response 4.068e-22 215 715
3 Tissue remodeling and wound repair 2.392e-19 168 534
4 Immune system response 2.051e-15 249 973
5 DNA-damage response 4.809e-14 114 354
6 Cell cycle and its regulation 6.934e-14 134 444
7 Apoptosis 1.836e-13 217 846
8 Mitogenic signaling 1.894e-13 158 560
9 Calcium signaling 1.913e-12 127 430
10 Cardiac hypertrophy 5.033e-12 70 190
11 Vasodilation 1.730e-9 98 336
12 Vascular development (angiogenesis) 1.790e-9 137 520
13 Hematopoiesis 3.383e-9 89 299
14 Cystic fibrosis disease 7.457e-7 150 636
15 Protein synthesis 7.583e-7 83 304
16 Protein degradation 1.106e-6 75 269
17 Vasoconstriction 4.797e-5 78 311
18 Myogenesis regulation 1.054e-3 28 95
19 Blood clotting 1.535e-3 65 278
20 Transcription regulation 4.933e-3 8 18
Pathway
maps
1 Cytoskeleton remodeling_TGF, WNT and cytoskeletal
remodeling
1.153E-11 47 111
2 Cytoskeleton remodeling_Cytoskeleton remodeling 2.479E-11 44 102
3 Cell adhesion_Chemokines and adhesion 7.871E-10 41 100
4 Cytoskeleton remodeling_FAK signaling 3.013E-09 28 57
5 Cytoskeleton remodeling_Regulation of actin
cytoskeleton by Rho GTPases
9.497E-09 16 23
6 Signal transduction_JNK pathway 3.362E-08 22 42
7 Cytoskeleton remodeling_Role of PKA in cytoskeleton
reorganisation
6.569E-08 21 40
8 Signal transduction_Erk interactions: Inhibition of Erk 7.428E-08 19 34
9 Cardiac hypertrophy_NF-AT signaling in cardiac
hypertrophy
1.099E-07 28 65
10 G-protein signaling_RAC1 in cellular process 1.388E-07 19 35
11 Immune response _CCR3 signaling in eosinophils 1.513E-07 31 77
12 Development_Thrombopoietin-regulated cell processes 1.675E-07 22 45
13 Development_A2A receptor signaling 3.276E-07 21 43
14 Development_HGF signaling pathway 4.398E-07 22 47
15 G-protein signaling_G-Protein alpha-12 signaling pathway 4.410E-07 19 37
16 Immune response_Gastrin in inflammatory response 4.963E-07 28 69
17 Development_ERK5 in cell proliferation and neuronal
survival
9.780E-07 14 23
18 Immune response_HMGB1/RAGE signaling pathway 1.280E-06 23 53
19 Development_Endothelin-1/EDNRA signaling 1.280E-06 23 53
20 Cell cycle_Influence of Ras and Rho proteins on G1/S
transition
1.280E-06 23 53
doi:10.1371/journal.pone.0087547.t001
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The first ontology examined was ‘‘Pathway Maps,’’ which
groups genes into cellular processes, protein functions, and
diseases. The top 20 most significantly enriched pathways within
the Pathway Maps ontology included cytoskeleton remodeling, G-
protein signaling, and NF-AT signaling in cardiac hypertrophy
(Fig. 7, Table 1). Next, Map Folder ontology, which is a higher
order analysis of the Pathway Maps ontology, was applied. Map
Folder ontology group genes together from the Pathway Maps
database according to main biological processes. The top
pathways identified by the Map Folder ontology included cell
Table 2. Top 20 most significantly enriched pathways analyzed with MetaCoreTMontology (N= 2).
# Pathways p-value
# of changed
genes
# of genes in
pathway
Disease
pathways
1 Psychiatry and psychology 2.383E-11 856 2837
2 Mental disorders 5.433E-11 848 2817
3 Heart diseases 2.347E-10 404 1227
4 Pathological conditions, signs and symptoms 1.042E-08 1191 4182
5 Familial hypertrophic cardiomyopathy 8.802E-08 15 17
6 Pathologic processes 9.621E-08 789 2694
7 Sensation disorders 3.025E-07 114 296
8 Nervous system diseases 3.070E-07 1344 4828
9 Myocardial ischemia 4.967E-07 261 793
10 Signs and symptoms 6.613E-07 717 2453
11 Functional colonic diseases 1.173E-06 23 36
12 Irritable bowel syndrome 1.173E-06 23 36
13 Anorexia 1.178E-06 32 58
14 Tobacco use disorder 1.589E-06 116 311
15 Renal insufficiency 2.090E-06 105 277
16 Vesico-ureteral reflux 4.129E-06 16 22
17 Short bowel syndrome 4.265E-06 9 9
18 Myocardial infarction 7.675E-06 149 430
19 Body weight changes 1.748E-05 67 167
20 Urologic diseases 2.104E-05 457 1539
Process
networks
1 Cytoskeleton_Regulation of cytoskeleton
rearrangement
9.303E-11 88 183
2 Cytoskeleton_Actin filaments 2.240E-05 71 176
3 Muscle contraction 2.270E-05 70 173
4 Cell adhesion_Cadherins 5.363E-05 71 180
5 Cell adhesion_Leucocyte chemotaxis 5.398E-05 79 205
6 Signal Transduction_Cholecystokinin signaling 7.924E-05 46 106
7 Development_Neurogenesis_Axonal guidance 9.138E-05 86 230
8 Development_ERK5 in cell proliferation and
neuronal survival
1.878E-04 15 24
9 Reproduction_Spermatogenesis, motility and copulation 6.576E-04 82 229
10 Signal transduction_WNT signaling 1.103E-03 65 177
11 Proliferation_Positive regulation cell proliferation 1.416E-03 78 221
12 Cell adhesion_Platelet aggregation 3.250E-03 62 174
13 Cell adhesion_Integrin-mediated cell-matrix adhesion 3.411E-03 74 214
14 Reproduction_Male sex differentiation 4.308E-03 83 246
15 Signal transduction_NOTCH signaling 4.369E-03 80 236
16 Muscle contraction_Nitric oxide signaling in the
cardiovascular system
5.285E-03 46 125
17 Neurophysiological process_Transmission of nerve impulse 6.304E-03 72 212
18 Cell cycle_Mitosis 6.696E-03 62 179
19 Cardiac development_BMP_TGF beta signaling 7.037E-03 43 117
20 Cardiac development_FGF_ErbB signaling 7.692E-03 45 124
doi:10.1371/journal.pone.0087547.t002
Caffeine Acts via A1ARs to Alter Cardiac Function
PLOS ONE | www.plosone.org 10 January 2014 | Volume 9 | Issue 1 | e87547
differentiation, cardiac hypertrophy, and vascular development
(Fig. 7, Table 1).
The Process Networks ontology uses data from Pathway Maps,
GO-processes, and network models of main cellular processes to
identify significant gene pathways. The top 20 pathways identified
by Process Network ontology included those involved with
cytoskeleton regulation, cardiac development - BMP/TGF-beta
signaling, and cardiac development – FGF/ErbB signaling (Fig. 7,
Table 2).
The forth ontology examined, Disease (by Biomarker), uses
biomarkers to group the genes into disease pathways. The Disease
(by Biomarkers) ontology identified heart diseases, cardiomyopa-
thy, myocardial ischemia, myocardial infarction, and body weight
changes as some of the most significant pathways in this ontology
analysis (Figs. 7–8, Table 2). There were many significantly
enriched pathways related to the cardiovascular system including
those related to cardiac disease, cardiac hypertrophy, and cardiac
development and all these significant pathways are displayed
together along with their P-values and the percentage of genes in
the specific pathway that are affected (Fig. 7). Some pathways
associated with growth were identified, but only four of these
pathways had significant P-values (Fig. 8).
Further pathway analysis was performed by importing the genes
associated with DMRs into the Ingenuity Pathway Analysis (IPA)
software. This analysis identified cardiac specific pathways in
several larger ontologies including Diseases and Disorders,
Physiological Development, Top Toxicity Lists, and Cardiotoxic-
ity (Table 3). Many cardiac pathways were identified with the
Ingenuity database including Cardiovascular Disease, Organ
Development, Cardiac Hypertrophy, and Cardiac Output
(Table 3). Many of the pathways found with Ingenuity were
similar to those identified with the MetaCore software (Table 1,
Fig. 7).
Of the top 20 most significant cardiovascular pathways
identified from the different ontologies in MetaCore, five were
related to cardiac hypertrophy and four were related to cardiac
development (Fig. 7). Further analysis, of the genes affected within
the hypertrophic cardiomyopathy ontology (Fig. 7), identified
many structural genes including troponin I (Tnni3), troponin T
(Tnnt2), troponin C (Tnnc1), a-actin C1 (Actc1) that are important
for proper cardiac function (Table 4). In addition, 9 of the 40
genes associated with DMRs in the hypertrophic cardiomyopathy
ontology express myosin heavy chain genes, including 2 that are
critical for heart function and development, myosin heavy peptide
6 alpha (Myh6) and myosin heavy peptide 7 beta (Myh7; Table 4).
Analysis of a more specific ontology, cardiac hypertrophy – NF-
AT signaling, revealed similar genes as the general hypertrophic
cardiomyopathy ontology such as Myh6, Myh7, Tnnt2, Tnni3, and
Actc1 (Fig. 7; Table 5). The NF-AT ontology identified transcrip-
tion factors that were associated with DMRs including GATA
binding protein 4 (Gata4), myocyte enhancer factor 2c (Mef2c), and
the transcriptional co-activator calmodulin binding transcription
Figure 8. Significantly enriched body weight related pathways.
Gene set enrichment analysis was performed with the differentially
methylated genes between A1AR+/+ mice treated with or without
caffeine. The analysis was conducted with MetaCore Enrichment
Analysis using the ontologies of Diseases (by Biomarkers), Map Folders,
Pathway Maps, and Process Networks. Bars represent the percentage of
altered methylation genes (in black) within a pathway. The numbers of
altered genes and genes in a pathway are listed next to the bars. Dots
indicate the negative log 10 of the P-values. Larger –log(P-value) means
that the pathway is more significant. The threshold for significance is
marked in the graph as a dotted-line at 1.3 (2log(0.05)). N = 2.
doi:10.1371/journal.pone.0087547.g008
Table 3. Significantly enriched miRNA pathways from Ingenuity Pathway Analysis following in utero caffeine exposure. (N = 2).
Top pathways p-value # of changed genes
Diseases and disorders Reproductive system disease 9.04E-17 18
Cancer 1.61E-14 26
Hematological disease 1.97E-12 10
Endocrine system disorders 1.27E-11 16
Inflammatory disease 1.03E-09 11
Physiological development Connective tissue development and function 1.39E-03 4
Nervous system development and function 2.22E-03 1
Respiratory system development and function 2.22E-03 1
Tissue development 2.22E-03 3
Tumor morphology 2.22E-03 2
Cardiotoxicity Cardiac inflammation 4.78E-06 2
Congenital heart anomaly 2.60E-04 2
Cardiac dilation 4.14E-02 1
Cardiac infarction 4.51E-02 2
Pulmonary hypertension 4.78E-02 1
doi:10.1371/journal.pone.0087547.t003
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activator 2 (Camta2; Table 5). In addition, 9 out of the 28 affected
genes in this pathway are guanine nucleotide binding proteins (G-
proteins; Table 5).
To elaborate on the DNA methylation array results, we selected
several DMRs at different gene loci related to cardiac hypertrophy
including Mef2c, Tnnt2, Myh6, Myh7, and Gata4 and body weight
Ins2 for bisulfite sequencing. Of the six genes examined by BS-
sequencing, 3 of them matched the DNA methylation array results
including Mef2c and Ins2 which were both hypermethylated and
Myh6 which was hypomethylated in caff+/+ (Table 6). Two genes,
Gata4 and Myh7, showed no difference by BS-seq in caff+/+ even
though they were both hypermethylated in the DNA methylation
array results (Table 6). One gene, Tnnt2, was hypomethylated in
Table 4. Genes in the hypertrophic cardiomyopathy pathway with differentially methylated regions following in utero caffeine
exposure. (N = 2).
Gene symbol Accession Fold change P-value Feature
Myl3 BC061222 1.72 8.32E-05 Promoter
Bat5 (HLA-B) NM_178592 1.63 1.58E-03 Transcript & CpG islands
Myh14 (MyHC/Myosin II) NM_028021 1.58 3.47E-05 Promoter
ANP BC089615 1.57 6.76E-04 Promoter
Cav3 (Caveolin-3) NM_007617 1.57 8.13E-04 Transcript
Myh11 (MyHC/Myosin II) NM_001161775 1.56 2.57E-04 Transcript
Oxtr (Galpha(q)-specific peptide GPCRs) NM_001081147 1.50 9.77E-04 Transcript
PKC-beta2/cPKC (conventioanal) NM_008855 1.49 1.05E-03 Promoter
Pla2g2a (PLA2) NM_001082531 1.48 1.29E-03 Transcript
Cyp11b2 BC119321 1.48 3.89E-04 Promoter
Pla2g5 (PLA2) NM_001122954 1.47 5.62E-03 Transcript
Myh7 (MyHC/Myosin II/beta-MHC) BC121789 1.46 6.31E-04 Transcript
Mylpf (MRLC/Myosin II) NM_016754 1.43 1.17E-03 Promoter
Vcl (Vinculin) BC008520 1.42 1.12E-03 Promoter
Ndufv2 BC030946 1.41 1.07E-03 Transcript
Ppargc1b BC150699 1.40 1.74E-04 Promoter
Myh13 (MyHC/Myosin II) NM_001081250 1.40 1.66E-03 Promoter
Vwf (von Willebrand factor) NM_011708 1.38 1.29E-03 Transcript
Myh10 (MyHC/Myosin II) BC089011 1.37 3.31E-03 Transcript
PKC NM_008860 1.37 9.77E-04 Transcript
Tnni3 (Troponin I, cardiac) BC100590 1.35 1.38E-03 Transcript
Ppargc1 (PGC1-alpha) NR_027710 1.34 9.33E-04 Transcript
Myl1 (MELC/Myosin II) NM_021285 1.31 2.00E-03 Promoter & transcript
Actb (Actin) NM_007393 1.31 2.19E-03 Promoter
Igf1r BC138869 1.30 2.40E-03 Transcript
Ppm1a (PP2C) NM_008910 1.30 4.17E-03 Promoter
Edn2 (Endothelin-2) BC037042 1.26 1.48E-03 Promoter
Actc1 (Actin) BC062138 1.26 4.07E-03 Promoter
Myh1 (MyHC/Myosin II) NM_030679 1.24 9.33E-04 Transcript
Blat3 (HLA-B) NM_057171 1.24 1.55E-03 Promoter
Myl1 (MELC) NM_021285 1.23 2.14E-03 Transcript
Myh8 (MyHC/Myosin II) NM_177369 1.19 1.32E-03 Promoter
Myoz2 BC024360 -1.24 2.57E-03 Promoter
Ace1 NM_009598 -1.31 1.91E-04 Promoter
Igfbp1 (IBP1) BC013345 -1.40 1.05E-03 Promoter
LOC547349 (MHC class I) NM_001025208 -1.43 3.02E-03 Promoter
Tnnt2 (Troponin T, cardiac) NM_001130176 -1.51 5.62E-04 Promoter
Myh6 (MyHC/Myosin II/alpha-MHC) NM_010856 -1.52 2.04E-04 Promoter
Lamp2 NM_001017959 -1.52 7.59E-04 Promoter
Mybpc3 (Cardiac MyBP-C) NM_008653 -1.58 4.17E-03 Promoter
Tnnc1 (Troponin C, cardiac) NM_009393 -1.66 1.35E-03 Promoter
doi:10.1371/journal.pone.0087547.t004
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the caff+/+ group in the array but hypermethylated by BS-seq.
(Table 6).
To determine if the DNA methylation changes observed
between veh+/+ and caff+/+ affect gene expression, we performed
quantitative real-time PCR. We examined the gene expression of
Mef2c, Tnnt2, Myh6, and Myh7 in adult left ventricles. Hyper-
methylation of DNA is generally associated with a decrease in gene
expression and this was observed for Mef2c but not Myh7,
indicating that DNA methylation changes seen for Myh7 does
not affect expression (Fig. 9). Hypomethylation of DNA is
generally associated with an increase in gene expression, and that
was observed for Myh6 (Fig. 9).
Analysis of DMRs associated with miRNA sites and promoters
identified many pathways and genes related to cardiovascular
biology. Using the IPA software, several Cardiotoxicity Pathways
were identified including cardiac inflammation, cardiac dilation,
and cardiac infarction (Table 7). Analysis of the miRNA regions
identified 103 regions that were significantly differentially meth-
ylated (Table 8). Of the miRNA promoter regions with DMRs,
two were related to cardiac hypertrophy including miR-208b and
Table 5. Genes in the cardiac hypertrophy NF-AT signaling pathway with differentially methylated regions following in utero
caffeine exposure. (N = 2).
Gene symbol Accession Fold change P-value Feature
Gng3 (G-protein beta/gamma) BC029680 1.93 1.51E-03 Promoter
Ctf1 (Cardiotrophin-1) NM_007795 1.64 8.13E-04 Promoter
Gnai3 (G-protein alpha-i family) NM_010306 1.63 1.86E-03 Promoter
ANP BC089615 1.57 6.76E-04 Promoter
Camta2 BC056395 1.57 5.25E-04 Promoter
Lif NM_001039537 1.52 2.69E-04 Transcript
Gng10 (G-protein beta/gamma) NM_025277 1.51 1.86E-03 Transcript
Pik3r2 NM_008841 1.49 3.39E-05 Transcript
Gng8 (G-protein beta/gamma) NM_010320 1.47 8.51E-03 Promoter & transcript
Myh7 (beta-MHC) NM_080728 1.46 6.31E-04 Transcript
Ark (PKB) NM_001110208 1.45 1.23E-03 Promoter
Mef2c NM_025282 1.44 2.75E-04/ Promoter
Gnas (G-protein alpha-s) NM_022000 1.43 3.55E-09 Transcript & CpG island
Shc1 NM_001113331 1.43 5.37E-04 Transcript
Adssl1 NM_007421 1.41 3.55E-03 Promoter
Map2k5 BC028260 1.40 1.10E-03 Transcript
Gng5 (G-protein beta/gamma) NM_010318 1.37 1.02E-03 Promoter
Tnni3 (Troponin I, cardiac) BC100590 1.35 1.38E-03 Promoter & transcript
Gsk3b NM_019827 1.34 2.63E-03 Transcript
PKC-epsilon NM_011104 1.34 5.13E-03 Promoter
Gata4 NM_008092 1.32 6.17E-04 Promoter
Igf1r BC138869 1.32 2.40E-03 Promoter & CpG island
Actc1 (actin) BC062138 1.26 4.07E-03 Promoter
Gnb3 (G-protein beta/gamma) NM_013530 1.25 6.76E-04 Promoter & transcript
Gngt (G-protein beta/gamma) NM_010314 1.23 3.09E-03 Transcript
Ppp3cb (Calcineurin A, catalytic) NM_008914 1.22 2.00E-03 Transcript
Gng2 (G-protein beta/gamma) NM_010315 1.18 1.95E-03 Transcript
Mef2d BC011070 1.18 1.74E-03 Transcript
Gnb11 (G-protein beta/gamma) NM_001081682 21.21 7.41E-04 Promoter
Gngt2 (G-protein beta/gamma) NM_001038664 21.43 1.00E-03 Promoter
Gnaz (G-protein alpha-i family) BC014702 21.43 2.19E-03 Promoter
Tnnt2 (Troponin T, cardiac) NM_001130176 21.51 5.62E-04 Promoter
Myh6 (alpha-MHC) NM_010856 21.52 2.04E-04 Promoter
Mybpc3 (Cardiac MyBP-C) NM_008653 21.58 4.17E-03 Promoter
MAPK5 BC100398 21.59 1.02E-03 Promoter
Calm3 (Calmodulin) BC050926 21.60 2.00E-04 Promoter
Ppp3cc (Calcineurin A, catalytic) BC141079 21.62 2.19E-04 Promoter
Pik3cd (PI3K cat class IA) NM_001029837 21.83 2.29E-03 Promoter
doi:10.1371/journal.pone.0087547.t005
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miR-499 (Table 8) [49,50]. These miRNAs are located within
introns of the Myh7 and Myh7b genes. MiR-208b is located within
intron 31 of the Myh7 gene which is also differentially methylated
and miR-499 is located in intron 19 of Myh7b. However, unlike
Myh7 which was hypermethylated, regions within the promoter for
both miR-208b and miR499 were hypomethylated.
Caffeine induces a decrease in global DNA methylation
The DNA methylation array interrogates the portion of the
genome that is associated with promoter regions, CpG islands, and
miRNA regions. To assess DNA methylation throughout the
whole genome, a methylated DNA quantification assay was
performed. The whole genome DNA methylation level was
compared between veh+/+ and caff+/+ or veh+/2 and caff+/2
using DNA isolated from adult left ventricles. Caffeine treatment
caused a 26% decrease in global DNA methylation in A1AR+/+
hearts, but no change in the level of DNA methylation was
detected in the A1AR+/2 hearts (Fig. 10). In addition, no
significant change in global DNA hydroxymethylation was
detected in either A1AR+/+ or A1AR+/2 adult hearts following
in utero caffeine exposure (Fig. 10).
Discussion
Our previous research demonstrated that A1ARs protect the
developing embryo from intra-uterine hypoxia [51,52]. The loss of
A1AR expression in embryos leads to increased embryonic death
and severe growth retardation under hypoxic conditions [51,52].
Further studies demonstrated that hypoxia and/or caffeine
treatment, which inhibits A1AR signaling, during embryogenesis
had long-lasting effects into adulthood both on cardiac function
and body weight [14]. We now demonstrate the importance of
normal adenosine signaling through A1ARs during development,
as disruption in A1AR action through caffeine treatment leads to
increased body weight, reduced cardiac function, and altered
cardiac DNA methylation patterns in adulthood.
Previous studies revealed that in utero caffeine exposure led to
increased percent body fat in adult males but no difference in adult
body weight was detected [14]. In the current study, we observed
that in utero caffeine treatment increased body weight without a
change in proportion of body fat. The possible reason for these
differences vs. our previous studies may be related to the strain of
mice used. The original examination was performed on C57Bl/6,
an inbred strain from Charles River Laboratories; the current
study examined the A1AR knockout line that is on a mixed
background of 129/OlaHsd/C57Bl/6. The difference that we
observe in metabolic function between the different mouse strains
may be due to differences in DNA methylation changes in
response to caffeine treatment. Further experiments into the strain
differences in weight and body fat results will need to be
performed, especially on an outbred strain. In both strains
examined, it is important to note that early embryonic exposure
to caffeine induced long-term effects in adult mice.
As with previous studies [14], this study demonstrated altered
cardiac function, including decreased cardiac output. Previous
reports indicated that in utero caffeine exposure caused a decrease
Table 6. DNA methylation changes measured by bisulfite sequencing. (N = 2).
Gene name
Gene
symbol
Genbank
accession Strand
Distance
from TSS
veh+/+
methylation %
caff+/+
methylation % Difference
Myocyte enhancer
factor 2c
Mef2c NM_025282 + 2764 to 2583 75.2% 90.8% Increased 20.7%
Insulin II Ins2 AA986540 - 2699 to 2698 68.8% 100.0% Increased 45.3%
Insulin II Ins2 AA986540 - 2275 to 2274 79.2% 93.8% Increased 18.4%
Troponin T2, Cardiac Tnnt2 NM_001130176 + 22494 to 22015 31.8% 55.6% Increased 74.8%
Troponin T2, Cardiac Tnnt2 NM_001130176 + 21838 to 21496 17.6% 38.3% Increased 117.6%
Myosin, heavy
polypeptide 6, alpha
Myh6 NM_010856 - 22095 to 22094 25.0% 4.2% Decreased 595.2%
TSS: transcriptional start site, caff+/+: caffeine treated A1AR+/+ mice,
veh+/+: 0.09% saline treated A1AR+/+ mice.
doi:10.1371/journal.pone.0087547.t006
Figure 9. Relation between gene expression and DNA methyl-
ation. Expression of critical genes in the cardiac hypertrophy signaling
pathway was compared to their DNA methylation status measured by
DNA methylation array or bisulfite sequencing. A1AR+/+mice treated in
utero with either caffeine or vehicle were compared. Expression or
methylation differences are shown as fold-change of caffeine treat-
ments divided by normal saline controls. Gene expression results
represent data from three repeats of qPCR measurements (N = 3 per
group, genomic DNA and mRNA were extracted from left ventricles of
the same animals). Student’s t-test used and error bars are SEM. *
indicates P#0.05.
doi:10.1371/journal.pone.0087547.g009
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in fractional shortening [14]. In addition, this study identified
changes in heart morphology, including increased wall thickness
following in utero caffeine treatment. Previous research showed that
caffeine treatment affected the size of embryonic hearts [14]; in
this study we observed increased ventricular wall thickness in adult
hearts following early caffeine exposure. The increased ventricular
wall thickness resulted in reduced ventricular volume and reduced
cardiac output. The increased wall thickness and left ventricle
mass that we observed are consistent with cardiac concentric
hypertrophy, which is characterized by an increase in cardiac wall
thickness with a reduced chamber volume. These results suggest
that in utero caffeine exposure affects cardiac development, which
leads to concentric hypertrophy in adulthood to compensate for
reduced function. Concentric hypertrophy can eventually be
maladaptive when stroke volumes are reduced and diastolic
function is compromised.
Altered DNA methylation represents a potential mechanism for
translating in utero exposure to caffeine into the phenotypic changes
observed in adult mice, including increased body weight and
cardiac hypertrophy. The developing embryo and heart are
sensitive to factors that can alter DNA methylation at early
embryonic stages including E8.5 [40], the stage at which we
treated pregnant dams with caffeine. DNA demethylation and de
novo DNA methylation are actively and passively occurring during
early embryonic stages. After fertilization, paternal DNA is rapidly
demethylated and maternal DNA is passively demethylated until
implantation, when de novo DNA methylation increases between
E3.5 to E10.5 in mice [40]. This period is critical for re-
establishing DNA methylation patterns; therefore factors that
affect methylation during this time window could have long lasting
effects.
The ability of caffeine to alter DNA methylation and gene
expression has been demonstrated for the steroidogenic acute
regulatory protein (StAR) gene in adrenocortical cells [53]. A
change in StAR expression was attributed to the demethylation of a
single CpG site in the StAR promoter following caffeine treatment
[53]. Our analysis demonstrated that caffeine causes both a
genome-wide decrease in methylation, as well as a large number of
hypermethylated regions. The induction of both hyper- and hypo-
methylated DNA regions in the genome by caffeine was also
observed in cultured rat hippocampal neurons [15]. Although
these data may seem contradictory, a global decrease and regional
increase in DNA methylation has been observed in other
biological systems including cancer [54,55]. In addition, caffeine
exposure decreased promoter methylation in L6 rat myotubes that
was paralleled by an increase in the respective gene expression
[56]. These observations and our data may indicate that changes
in DNA methylation associated with caffeine treatment may be the
result of more than one pathway. For example, caffeine may affect
the activity or expression of both DNA methylation enzymes
(DNMTs) and demethylation agents (Tets). The altered activity of
these enzymes could then lead to the altered DNA methylation
patterns we and others observe. The genes affected by altered
DNA methylation may be dependent on the tissue and the timing
of treatment. For example, caffeine treatment at E8.5 leads to
altered DNA methylation and altered expression of genes
associated with cardiac hypertrophy in the adult heart.
Several cardiac hypertrophic pathways were identified with
altered DNA methylation patterns following caffeine treatment.
The cardiac hypertrophy pathway was identified within multiple
databases. Because the cardiac hypertrophy pathways identified by
ontology were consistent with the phenotype observed in adult
offspring of pregnant dams treated with caffeine, we further
analyzed the differentially methylated genes within these path-
ways. Although we discovered many genes associated with cardiac
hypertrophy that displayed altered DNA methylation patterns, not
all of these changes will necessarily affect gene expression. To
initially analyze the functional effects of altered DNA methylation
on gene expression, we performed bisulfite sequencing to identify
which DNA methylation sites were changed. Next, we performed
real-time PCR to examine the expression level of genes associated
with differentially methylated regions.
The first set of genes analyzed were part of the ‘‘NF-AT
signaling in cardiac hypertrophy’’ pathway. Cardiac hypertrophy
is mediated by three main transcription factors Mef2, NF-AT, and
Gata4 [57], and all of these genes were linked with changes in
DNA methylation in our analysis. We analyzed two of these genes
further (Mef2c and Gata4) and demonstrated that an increase in
Table 7. Significantly enriched miRNA pathways from Ingenuity Pathway Analysis following in utero caffeine exposure. (N = 2).
Top pathways p-value # of changed genes
Diseases and disorders Reproductive system disease 9.04E-17 18
Cancer 1.61E-14 26
Hematological disease 1.97E-12 10
Endocrine system disorders 1.27E-11 16
Inflammatory disease 1.03E-09 11
Physiological development Connective tissue development and function 1.39E-03 4
Nervous system development and function 2.22E-03 1
Respiratory system development and function 2.22E-03 1
Tissue development 2.22E-03 3
Tumor morphology 2.22E-03 2
Cardiotoxicity Cardiac inflammation 4.78E-06 2
Congenital heart anomaly 2.60E-04 2
Cardiac dilation 4.14E-02 1
Cardiac infarction 4.51E-02 2
Pulmonary hypertension 4.78E-02 1
doi:10.1371/journal.pone.0087547.t007
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methylation in the promoter region of Mef2c correlates with a
decrease in Mef2c gene expression in the adult heart. Further
analysis of NF-AT3 and Mef2d, which both show altered DNA
methylation patterns and are important factors during cardiac
hypertrophy, is also warranted [57].
We also analyzed myosin heavy chain alpha (Myh6) and myosin
heavy chain beta (Myh7), as their expression is altered during
cardiac hypertrophy [50,57]. During development Myh6 andMyh7
are expressed differently with Myh7 as the predominant fetal
Table 8. miRNAs with differentially methylated regions in
their promoters, 61.35 fold change cutoff. (N = 2).
Accession ID Fold change P-value
MI0009955 mmu-mir-1958 2.09 6.61E-04
MI0004636 mmu-mir-497 1.76 1.02E-04
MI0000237 mmu-mir-195 1.76 1.02E-04
MI0006295 mmu-mir-466j 1.76 1.62E-03
MI0005515 mmu-mir-504 1.76 3.89E-03
MI0000817 mmu-mir-335 1.73 6.31E-03
MI0000730 mmu-mir-7b 1.66 6.76E-04
MI0000233 mmu-mir-191 1.63 8.91E-04
MI0001447 mmu-mir-425 1.63 8.91E-04
MI0009948 mmu-mir-1953 1.62 4.57E-05
MI0000394 mmu-mir-296 1.62 5.75E-04
MI0000398 mmu-mir-298 1.62 5.75E-04
MI0000584 mmu-mir-34a 1.56 3.31E-03
MI0009936 mmu-mir-1946a 1.55 2.24E-03
MI0000595 mmu-mir-324 1.54 3.63E-03
MI0009931 mmu-mir-1942 1.52 4.79E-04
MI0004652 mmu-mir-687 1.52 1.23E-03
MI0000570 mmu-mir-22 1.48 2.63E-04
MI0001165 mmu-mir-370 1.47 2.63E-04
MI0005496 mmu-mir-421 1.45 6.76E-04
MI0004125 mmu-mir-374 1.45 6.76E-04
MI0004123 mmu-mir-675 1.44 3.16E-06
MI0001146 mmu-mir-384 1.44 1.41E-03
MI0000691 mmu-mir-32 1.43 6.76E-04
MI0000702 mmu-mir-219-1 1.43 4.37E-03
MI0005482 mmu-mir-147 1.42 1.66E-03
MI0005521 mmu-mir-92b 1.41 2.04E-03
MI0000250 mmu-mir-207 1.41 7.94E-03
MI0009967 mmu-mir-1946b 1.39 4.57E-04
MI0000725 mmu-mir-125b-1 1.36 9.55E-04
MI0004258 mmu-mir-672 1.36 2.75E-03
MI0005552 mmu-mir-208b -1.36 1.00E-03
MI0010752 mmu-mir-2139 -1.36 1.62E-03
MI0000171 mmu-mir-149 -1.40 1.05E-03
MI0000227 mmu-mir-185 -1.40 2.24E-03
MI0009963 mmu-mir-1966 -1.43 1.41E-04
MI0004676 mmu-mir-499 -1.43 2.82E-03
MI0000799 mmu-mir-382 -1.44 2.04E-04
MI0000160 mmu-mir-134 -1.44 2.04E-04
MI0004134 mmu-mir-668 -1.44 2.04E-04
MI0003492 mmu-mir-485 -1.44 2.04E-04
MI0005497 mmu-mir-453 -1.44 2.04E-04
MI0000176 mmu-mir-154 -1.44 2.04E-04
MI0004589 mmu-mir-496 -1.44 2.04E-04
MI0000730 mmu-mir-7b -1.44 4.47E-03
MI0000583 mmu-mir-96 -1.46 5.13E-04
MI0000225 mmu-mir-183 -1.46 5.13E-04
MI0005475 mmu-mir-882 -1.47 2.40E-03
Table 8. Cont.
Accession ID Fold change P-value
MI0003484 mmu-mir-483 -1.48 1.29E-04
MI0008315 mmu-mir-1905 -1.52 7.08E-04
MI0004708 mmu-mir-721 -1.72 1.17E-03
MI0009918 mmu-mir-1929 -1.84 1.00E-02
MI0004688 mmu-mir-704 -1.91 1.82E-03
doi:10.1371/journal.pone.0087547.t008
Figure 10. Embryonic caffeine exposure leads to a decrease in
global DNA methylation. DNA was isolated from adult left ventricles
of mice treated in utero with caffeine. (A) The percentage of 5-
methylcytosine decreased in caff+/+ hearts compared to veh+/+
controls, but no change in global DNA methylation levels was observed
in caff+/2 hearts compared to veh+/2 hearts. (B) But there was no
change in the percentage of 5-hydroxymethylcytosine in the left
ventricular DNA in either the caff+/+ or caff+/2 hearts. N = 3 per group,
each sample was measured 3–4 times, student t-test, ** P = 0.0053).
doi:10.1371/journal.pone.0087547.g010
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isoform and Myh6 as the dominate form in adults mice [58]. Myh7
is still expressed in adulthood but an increase in its expression
during adulthood is a common feature of cardiac hypertrophy
[59]. Our analysis revealed that both Myh6 and Myh7 were up-
regulated at the level of gene expression. The increase in Myh6
expression was consistent with a decrease in DNA methylation in
its promoter region. However, DNA methylation analysis by both
BS-seq and methylation array indicated an increase in DNA
methylation in the Myh7 transcript region. This apparent
disconnect between DNA methylation status and gene expression
level for Myh7 may be explained in part by the fact that the
promoter region for miR-208b was hypomethylated. MiR-208b is
encoded within an intron of the Myh7 gene, such that an increase
in miR-208b expression could also result in an increase in Myh7
expression due to the fact that they are co-regulated [50]. We
observed by real-time PCR an up-regulation of Myh7 gene
expression which is consistent with the phenotype of cardiac
hypertrophy observed. Future analysis will focus on elucidating the
mechanism by which caffeine exposure causes changes in Myh6
and Myh7 methylation, and identifying the specific methylation
sites that are important for regulating their expression.
The changes observed with caffeine treatment were seen only
when A1ARs were expressed. Loss of A1ARs in the knockout mice
(A1AR2/2) protected the embryos and adults from effects of in
utero caffeine exposure. These findings indicate that A1ARs
mediate the effects of caffeine on the developing embryo that
lead to long-term changes in cardiac function and body weight as
well as long-term changes in DNA methylation patterns. Although
we observed changes in DNA methylation in response to caffeine
in the absence of A1AR expression, there were fewer differences
and we did not observe effects on cardiac function or body weight
in these treated mice. These data indicate that caffeine has specific
effects on DNA methylation by acting through A1ARs and
producing a specific phenotype. In addition, these results suggest
that embryonic and cardiac developments are sensitive to changes
in A1AR action.
Some of the limitations of this study include the number of
animals examined and using i.p. injection as the route of caffeine
administration, which is not the normal way of ingesting caffeine
in humans. Many parameters, including route of administration,
number of exposures including chronic exposure and peak serum
levels, need to be considered before commenting on the risk of
caffeine exposure in humans [60]. In our previous study, we did
not see differences in adult female percent body fat with in utero
caffeine treatment, which is one reason female mice were not
examined in this study [14]. Further studies on the effect of in utero
caffeine on females will need to be performed in order to overcome
this limitation. Caffeine has also been shown to have beneficial
effects in neurological and immunological disorders_ENREF_59
[61–63]. Thus further clinical and animal studies are needed to
assess the effectiveness and safety of caffeine treatment during
human pregnancy before recommendations can be made.
This report begins to answer an important question: does in utero
caffeine exposure increase the susceptibility of an individual
developing cardiac or metabolic disease in adulthood? This study
is an initial step that indicates that in utero caffeine exposure can
have long lasting effects into adulthood and that caffeine can alter
the DNA methylation pattern in the heart during early stages of
embryonic development.
Acknowledgments
We thank Ryan Poulsen and Sarah Renzi for technical assistance.
Author Contributions
Conceived and designed the experiments: DB XF SAR CCW. Performed
the experiments: DB XF VG CCW. Analyzed the data: DB XF VG HX
SAR CCW. Wrote the paper: XF SAR CCW.
References
1. Curtis LH, Hammill BG, Bethel MA, Anstrom KJ, Gottdiener JS, et al. (2007)
Costs of the metabolic syndrome in elderly individuals: findings from the
Cardiovascular Health Study. Diabetes Care 30: 2553–2558.
2. Balkau B, Valensi P, Eschwege E, Slama G (2007) A review of the metabolic
syndrome. Diabetes Metab 33: 405–413.
3. Cooper-DeHoff RM, Pepine CJ (2007) Metabolic syndrome and cardiovascular
disease: challenges and opportunities. Clin Cardiol 30: 593–597.
4. Obunai K, Jani S, Dangas GD (2007) Cardiovascular morbidity and mortality of
the metabolic syndrome. Med Clin North Am 91: 1169–1184, x.
5. Qiao Q, Gao W, Zhang L, Nyamdorj R, Tuomilehto J (2007) Metabolic
syndrome and cardiovascular disease. Ann Clin Biochem 44: 232–263.
6. Ogden CL, Yanovski SZ, Carroll MD, Flegal KM (2007) The epidemiology of
obesity. Gastroenterology 132: 2087–2102.
7. Browne ML (2006) Maternal exposure to caffeine and risk of congenital
anomalies: a systematic review. Epidemiology 17: 324–331.
8. Fredholm BB (1995) Astra Award Lecture. Adenosine, adenosine receptors and
the actions of caffeine. PharmacolToxicol 76: 93–101.
9. Turner CP, Seli M, Ment L, Stewart W, Yan H, et al. (2003) A1 adenosine
receptors mediate hypoxia-induced ventriculomegaly. Proc Natl Acad Sci USA
100: 11718–11722.
10. Koos BJ, Mason BA, Ervin MG (1994) Adenosine mediates hypoxic release of
arginine vasopressin in fetal sheep. Am J Physiol 266: R215–220.
11. Rivkees SA, Zhao Z, Porter G, Turner C (2001) Influences of adenosine on the
fetus and newborn. Mol Genet Metab 74: 160–171.
12. Fredholm BB, Abbracchio MP, Burnstock G, Daly JW, Harden TK, et al. (1994)
Nomenclature and classification of purinoceptors. Pharmacol Rev 46: 143–156.
13. Rivkees SA (1995) The ontogeny of cardiac and neural A1 adenosine receptor
expression in rats. Brain Res Dev Brain Res 89: 202–213.
14. Wendler CC, Busovsky-McNeal M, Ghatpande S, Kalinowski A, Russell KS, et
al. (2009) Embryonic caffeine exposure induces adverse effects in adulthood.
FASEB J 23: 1272–1278.
15. Xu D, Zhang B, Liang G, Ping J, Kou H, et al. (2012) Caffeine-induced
activated glucocorticoid metabolism in the hippocampus causes hypothalamic-
pituitary-adrenal axis inhibition in fetal rats. PLoS One 7: e44497.
16. Christian MS, Brent RL (2001) Teratogen update: evaluation of the
reproductive and developmental risks of caffeine. Teratology 64: 51–78.
17. Ross CP, Persaud TV (1986) Cardiovascular primordium of the rat embryo
following in utero exposure to alcohol and caffeine. Can J Cardiol 2: 160–163.
18. Ross CP, Persaud TV (1986) Early embryonic development in the rat following
in utero exposure to alcohol and caffeine. Histol Histopathol 1: 13–17.
19. Matsuoka R, Uno H, Tanaka H, Kerr CS, Nakazawa K, et al. (1987) Caffeine
induces cardiac and other malformations in the rat. Am J Med Genet Suppl 3:
433–443.
20. Yeh CH, Liao YF, Chang CY, Tsai JN, Wang YH, et al. (2012) Caffeine
treatment disturbs the angiogenesis of zebrafish embryos. Drug Chem Toxicol.
21. Buscariollo DL, Breuer GA, Wendler CC, Rivkees SA (2011) Caffeine acts via
A1 adenosine receptors to disrupt embryonic cardiac function. PLoS One 6:
e28296.
22. Abdelkader TS, Chang SN, Kim TH, Song J, Kim DS, et al. (2012) Exposure
time to caffeine affects heartbeat and cell damage-related gene expression of
zebrafish Danio rerio embryos at early developmental stages. J Appl Toxicol.
23. Imamura S, Kimura M, Hiratsuka E, Takao A, Matsuoka R (1992) Effect of
caffeine on expression of cardiac myosin heavy chain gene in adult hypothyroid
and fetal rats. Circ Res 71: 1031–1038.
24. Cnattingius S, Ekbom A, Granath F, Rane A (2003) Caffeine intake and the risk
of spontaneous abortion. Food Chem Toxicol 41: 1202; author reply 1203.
25. Cnattingius S, Signorello LB, Anneren G, Clausson B, Ekbom A, et al. (2000)
Caffeine intake and the risk of first-trimester spontaneous abortion. N Engl J Med
343: 1839–1845.
26. Signorello LB, Nordmark A, Granath F, Blot WJ, McLaughlin JK, et al. (2001)
Caffeine metabolism and the risk of spontaneous abortion of normal karyotype
fetuses. Obstet Gynecol 98: 1059–1066.
27. Rivkees SA, Wendler CC (2012) Regulation of cardiovascular development by
adenosine and adenosine-mediated embryo protection. Arterioscler Thromb
Vasc Biol 32: 851–855.
28. Rivkees SA, Wendler CC (2011) Adverse and protective influences of adenosine
on the newborn and embryo: implications for preterm white matter injury and
embryo protection. Pediatr Res 69: 271–278.
29. Vik T, Bakketeig LS, Trygg KU, Lund-Larsen K, Jacobsen G (2003) High
caffeine consumption in the third trimester of pregnancy: gender-specific effects
on fetal growth. Paediatr Perinat Epidemiol 17: 324–331.
Caffeine Acts via A1ARs to Alter Cardiac Function
PLOS ONE | www.plosone.org 17 January 2014 | Volume 9 | Issue 1 | e87547
30. Weng X, Odouli R, Li DK (2008) Maternal caffeine consumption during
pregnancy and the risk of miscarriage: a prospective cohort study. Am J Obstet
Gynecol.
31. Larroque B, Kaminski M, Lelong N, Subtil D, Dehaene P (1993) Effects of birth
weight of alcohol and caffeine consumption during pregnancy. Am J Epidemiol
137: 941–950.
32. Murgatroyd C, Patchev AV, Wu Y, Micale V, Bockmuhl Y, et al. (2009)
Dynamic DNA methylation programs persistent adverse effects of early-life
stress. Nat Neurosci 12: 1559–1566.
33. Jirtle RL, Skinner MK (2007) Environmental epigenomics and disease
susceptibility. Nat Rev Genet 8: 253–262.
34. Dolinoy DC, Weidman JR, Jirtle RL (2007) Epigenetic gene regulation: linking
early developmental environment to adult disease. Reprod Toxicol 23: 297–307.
35. Waterland RA, Jirtle RL (2003) Transposable elements: targets for early
nutritional effects on epigenetic gene regulation. Mol Cell Biol 23: 5293–5300.
36. Ho SM, Tang WY, Belmonte de Frausto J, Prins GS (2006) Developmental
exposure to estradiol and bisphenol A increases susceptibility to prostate
carcinogenesis and epigenetically regulates phosphodiesterase type 4 variant 4.
Cancer Res 66: 5624–5632.
37. Johansson B, Halldner L, Dunwiddie TV, Masino SA, Poelchen W, et al. (2001)
Hyperalgesia, anxiety, and decreased hypoxic neuroprotection in mice lacking
the adenosine A1 receptor. Proc Natl Acad Sci USA 98: 9407–9412.
38. Olson EN (2004) A decade of discoveries in cardiac biology. Nat Med 10: 467–
474.
39. Gittenberger-de Groot AC, Bartelings MM, Deruiter MC, Poelmann RE (2005)
Basics of cardiac development for the understanding of congenital heart
malformations. Pediatr Res 57: 169–176.
40. He XJ, Chen T, Zhu JK (2011) Regulation and function of DNA methylation in
plants and animals. Cell Res 21: 442–465.
41. Cline GW, Vidal-Puig AJ, Dufour S, Cadman KS, Lowell BB, et al. (2001) In
vivo effects of uncoupling protein-3 gene disruption on mitochondrial energy
metabolism. J Biol Chem 276: 20240–20244.
42. Jacoby JJ, Kalinowski A, Liu MG, Zhang SS, Gao Q, et al. (2003)
Cardiomyocyte-restricted knockout of STAT3 results in higher sensitivity to
inflammation, cardiac fibrosis, and heart failure with advanced age. Proc Natl
Acad Sci USA 100: 12929–12934.
43. Momoi N, Tinney JP, Liu LJ, Elshershari H, Hoffmann PJ, et al. (2008) Modest
maternal caffeine exposure affects developing embryonic cardiovascular function
and growth. Am J Physiol Heart Circ Physiol 294: H2248–2256.
44. Palmke N, Santacruz D, Walter J (2011) Comprehensive analysis of DNA-
methylation in mammalian tissues using MeDIP-chip. Methods 53: 175–184.
45. Zilberman D, Gehring M, Tran RK, Ballinger T, Henikoff S (2007) Genome-
wide analysis of Arabidopsis thaliana DNA methylation uncovers an
interdependence between methylation and transcription. Nat Genet 39: 61–69.
46. Workman C, Jensen LJ, Jarmer H, Berka R, Gautier L, et al. (2002) A new non-
linear normalization method for reducing variability in DNA microarray
experiments. Genome Biol 3: research0048.
47. Liu T, Ortiz JA, Taing L, Meyer CA, Lee B, et al. (2011) Cistrome: an
integrative platform for transcriptional regulation studies. Genome Biol 12: R83.
48. Fang X, Thornton C, Scheffler BE, Willett KL (2013) Benzo[a]pyrene decreases
global and gene specific DNA methylation during zebrafish development.
Environ Toxicol Pharmacol 36: 40–50.
49. Espinoza-Lewis RA, Wang DZ (2012) MicroRNAs in heart development. Curr
Top Dev Biol 100: 279–317.
50. Callis TE, Pandya K, Seok HY, Tang RH, Tatsuguchi M, et al. (2009)
MicroRNA-208a is a regulator of cardiac hypertrophy and conduction in mice.
J Clin Invest 119: 2772–2786.
51. Wendler CC, Amatya S, McClaskey C, Ghatpande S, Fredholm BB, et al.
(2007) A1 adenosine receptors play an essential role in protecting the embryo
against hypoxia. Proc Natl Acad Sci USA 104: 9697–9702.
52. Wendler CC, Poulsen RR, Ghatpande S, Greene RW, Rivkees SA (2010)
Identification of the heart as the critical site of adenosine mediated embryo
protection. BMC Dev Biol 10: 57.
53. Ping J, Lei YY, Liu L, Wang TT, Feng YH, et al. (2012) Inheritable stimulatory
effects of caffeine on steroidogenic acute regulatory protein expression and
cortisol production in human adrenocortical cells. Chem Biol Interact 195: 68–
75.
54. Jones PA, Baylin SB (2007) The epigenomics of cancer. Cell 128: 683–692.
55. Laird PW (2003) The power and the promise of DNA methylation markers. Nat
Rev Cancer 3: 253–266.
56. Barres R, Yan J, Egan B, Treebak JT, Rasmussen M, et al. (2012) Acute exercise
remodels promoter methylation in human skeletal muscle. Cell Metab 15: 405–
411.
57. Frey N, Olson EN (2003) Cardiac hypertrophy: the good, the bad, and the ugly.
Annu Rev Physiol 65: 45–79.
58. Lompre AM, Nadal-Ginard B, Mahdavi V (1984) Expression of the cardiac
ventricular alpha- and beta-myosin heavy chain genes is developmentally and
hormonally regulated. J Biol Chem 259: 6437–6446.
59. Chien KR (2000) Genomic circuits and the integrative biology of cardiac
diseases. Nature 407: 227–232.
60. Brent RL, Christian MS, Diener RM (2011) Evaluation of the reproductive and
developmental risks of caffeine. Birth Defects Res B Dev Reprod Toxicol 92:
152–187.
61. Higdon JV, Frei B (2006) Coffee and health: a review of recent human research.
Crit Rev Food Sci Nutr 46: 101–123.
62. Simon DK, Swearingen CJ, Hauser RA, Trugman JM, Aminoff MJ, et al. (2008)
Caffeine and progression of Parkinson disease. Clin Neuropharmacol 31: 189–
196.
63. Daly JW (2007) Caffeine analogs: biomedical impact. Cell Mol Life Sci 64:
2153–2169.
Caffeine Acts via A1ARs to Alter Cardiac Function
PLOS ONE | www.plosone.org 18 January 2014 | Volume 9 | Issue 1 | e87547
